Zhen‐Bin Ding

机构：Fudan University, Zhongshan Hospital · ORCID：0000-0001-6613-8270

发表论文 176 篇 · 总被引 6549 次 · h-index 45

代表论文

• Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial (2025 · The Lancet · 被引 51)
• Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma (2024 · Nature Communications · 被引 47)
• Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study (2025 · The Lancet Oncology · 被引 20)
• Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma (2026 · New England Journal of Medicine · 被引 14)
• First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study (2025 · Signal Transduction and Targeted Therapy · 被引 8)
• Predictive value of neutrophil-to-lymphocyte ratio in recurrent HCC after repeat hepatectomy or salvage liver transplantation (2025 · Hepatology International · 被引 7)